Analysts at StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) in a note issued to investors on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reissued a “neutral” rating on shares of TRACON Pharmaceuticals in a research note on Monday, July 1st.
View Our Latest Stock Analysis on TCON
TRACON Pharmaceuticals Stock Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter. The company had revenue of $0.06 million during the quarter.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Featured Articles
- Five stocks we like better than TRACON Pharmaceuticals
- Short Selling: How to Short a Stock
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Insider Trades May Not Tell You What You Think
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.